Datopotamab

• Description :

  Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E) . Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer[1].

• UNSPSC :

  12352203

• Target :

  ADC Antibody; TROP2

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/datopotamab.html

• Purity :

  99.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Datopotamab]

• Molecular Weight :

  (145.28 kDa)

• References & Citations :

  [1]Okajima D, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Dec;20 (12) :2329-2340. |[2]Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2267989-53-5]